Cancer Chemotherapy: Targeting Folic Acid Synthesis

Overview

Journal Cancer Manag Res

Publisher Dove Medical Press

Specialty Oncology

Date 2011 Feb 9

PMID 21301589

Citations 60

Authors

Nicole Hagner

Markus Joerger

Affiliations

Soon will be listed here.

Abstract

Antifolates are structural analogs of folates, essential one-carbon donors in the synthesis of DNA in mammalian cells. Antifolates are inhibitors of key enzymes in folate metabolism, namely dihydrofolate reductase, β-glycinamide ribonucleotide transformylase, 5'-amino-4'-imidazolecarboxamide ribonucleotide transformylase, and thymidylate synthetase. Methotrexate is one of the earliest anticancer drugs and is extensively used in lymphoma, acute lymphoblastic leukemia, and osteosarcoma, among others. Pemetrexed has been approved in combination with cisplatin as first-line treatment for advanced non-squamous-cell lung cancer, as a single agent for relapsed non-small-cell lung cancer after platinum-containing chemotherapy, and in combination with cisplatin for the treatment of pleural mesothelioma. Raltitrexed is approved in many countries (except in the United States) for advanced colorectal cancer, but its utilization is mainly limited to patients intolerant to 5-fluorouracil. Pralatrexate has recently been approved in the United States for relapsed or refractory peripheral T-cell lymphoma. This article gives an overview of the cellular mechanism, pharmacology, and clinical use of classical and newer antifolates and discusses some of the main resistance mechanisms to antifolate drugs.

Citing Articles

Rational design, synthesis, and molecular modelling insights of dual DNA binders/DHFR inhibitors bearing arylidene-hydrazinyl-1,3-thiazole scaffold with apoptotic and anti-migratory potential in breast MCF-7 cancer cells.

El-Wakil M, Ghazala R, El-Dershaby H, Drozdowska D, Wrobel-Talalaj A, Parzych C J Enzyme Inhib Med Chem. 2025; 40(1):2468353.

PMID: 40035286 PMC: 11881662. DOI: 10.1080/14756366.2025.2468353.

Quinazoline Derivatives as Targeted Chemotherapeutic Agents.

Zayed M Cureus. 2024; 16(5):e60662.

PMID: 38899242 PMC: 11186210. DOI: 10.7759/cureus.60662.

Potential Hepatoprotective Effects of against Methotrexate-Induced Liver Injury: Integrated Phytochemical Profiling, Target Network Analysis, and Experimental Validation.

Fikry E, Orfali R, El-Sayed S, Perveen S, Ghafar S, El-Shafae A Antioxidants (Basel). 2023; 12(12).

PMID: 38136237 PMC: 10740566. DOI: 10.3390/antiox12122118.

Michael Adduct of Sulfonamide Chalcone Targets Folate Metabolism in Brugia Malayi Parasite.

Bhoj P, Bahekar S, Chowdhary S, Togre N, Amdare N, Jena L Biomedicines. 2023; 11(3).

PMID: 36979702 PMC: 10045823. DOI: 10.3390/biomedicines11030723.

Raltitrexed enhanced antitumor effect of anlotinib in human esophageal squamous carcinoma cells on proliferation, invasiveness, and apoptosis.

Zhen H, Tian J, Li G, Zhao P, Zhang Y, Che J BMC Cancer. 2023; 23(1):207.

PMID: 36870981 PMC: 9985835. DOI: 10.1186/s12885-023-10691-y.

References

Whetstine J, Flatley R, Matherly L . The human reduced folate carrier gene is ubiquitously and differentially expressed in normal human tissues: identification of seven non-coding exons and characterization of a novel promoter. Biochem J. 2002; 367(Pt 3):629-40. PMC: 1222932. DOI: 10.1042/BJ20020512. View

Johnson J, Meiering E, Wright J, Pardo J, Rosowsky A, Wagner G . NMR solution structure of the antitumor compound PT523 and NADPH in the ternary complex with human dihydrofolate reductase. Biochemistry. 1997; 36(15):4399-411. DOI: 10.1021/bi963039i. View

Rothem L, Aronheim A, Assaraf Y . Alterations in the expression of transcription factors and the reduced folate carrier as a novel mechanism of antifolate resistance in human leukemia cells. J Biol Chem. 2003; 278(11):8935-41. DOI: 10.1074/jbc.M209578200. View

Chen G, Wright J, Rosowsky A . Dihydrofolate reductase binding and cellular uptake of nonpolyglutamatable antifolates: correlates of cytotoxicity toward methotrexate-sensitive and -resistant human head and neck squamous carcinoma cells. Mol Pharmacol. 1995; 48(4):758-65. View

Green M, Chamberlain M . Renal dysfunction during and after high-dose methotrexate. Cancer Chemother Pharmacol. 2008; 63(4):599-604. DOI: 10.1007/s00280-008-0772-0. View

Smit E, Burgers S, Biesma B, Smit H, Eppinga P, Dingemans A . Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2009; 27(12):2038-45. DOI: 10.1200/JCO.2008.19.1650. View

Shen F, Ross J, Wang X, Ratnam M . Identification of a novel folate receptor, a truncated receptor, and receptor type beta in hematopoietic cells: cDNA cloning, expression, immunoreactivity, and tissue specificity. Biochemistry. 1994; 33(5):1209-15. DOI: 10.1021/bi00171a021. View

Grant S, Kris M, Young C, Sirotnak F . Edatrexate, an antifolate with antitumor activity: a review. Cancer Invest. 1993; 11(1):36-45. DOI: 10.3109/07357909309020259. View

Curt G, Jolivet J, Carney D, Bailey B, Drake J, Clendeninn N . Determinants of the sensitivity of human small-cell lung cancer cell lines to methotrexate. J Clin Invest. 1985; 76(4):1323-9. PMC: 424067. DOI: 10.1172/JCI112106. View

10.

Jansen G, Mauritz R, Drori S, Sprecher H, Kathmann I, Bunni M . A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. J Biol Chem. 1998; 273(46):30189-98. DOI: 10.1074/jbc.273.46.30189. View

11.

Shen F, Wu M, Ross J, Miller D, Ratnam M . Folate receptor type gamma is primarily a secretory protein due to lack of an efficient signal for glycosylphosphatidylinositol modification: protein characterization and cell type specificity. Biochemistry. 1995; 34(16):5660-5. DOI: 10.1021/bi00016a042. View

12.

Gorlick R, Goker E, Trippett T, Steinherz P, Elisseyeff Y, Mazumdar M . Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood. 1997; 89(3):1013-8. View

13.

Goldman I, LICHTENSTEIN N, OLIVERIO V . Carrier-mediated transport of the folic acid analogue, methotrexate, in the L1210 leukemia cell. J Biol Chem. 1968; 243(19):5007-17. View

14.

Sirotnak F, Wendel H, Bornmann W, Tong W, Miller V, Scher H . Co-administration of probenecid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivo. Clin Cancer Res. 2000; 6(9):3705-12. View

15.

OConnor O, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B . Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011; 29(9):1182-9. PMC: 3083873. DOI: 10.1200/JCO.2010.29.9024. View

16.

Allegra C, Hoang K, Yeh G, Drake J, Baram J . Evidence for direct inhibition of de novo purine synthesis in human MCF-7 breast cells as a principal mode of metabolic inhibition by methotrexate. J Biol Chem. 1987; 262(28):13520-6. View

17.

Jolivet J, Cowan K, Curt G, Clendeninn N, Chabner B . The pharmacology and clinical use of methotrexate. N Engl J Med. 1983; 309(18):1094-104. DOI: 10.1056/NEJM198311033091805. View

18.

Gifford A, Kavallaris M, Madafiglio J, Matherly L, Stewart B, Haber M . P-glycoprotein-mediated methotrexate resistance in CCRF-CEM sublines deficient in methotrexate accumulation due to a point mutation in the reduced folate carrier gene. Int J Cancer. 1998; 78(2):176-81. DOI: 10.1002/(sici)1097-0215(19981005)78:2<176::aid-ijc10>3.0.co;2-9. View

19.

Banerjee D, Mayer-Kuckuk P, Capiaux G, Budak-Alpdogan T, Gorlick R, Bertino J . Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochim Biophys Acta. 2002; 1587(2-3):164-73. DOI: 10.1016/s0925-4439(02)00079-0. View

20.

Kris M, Kinahan J, Gralla R, Fanucchi M, Wertheim M, OConnell J . Phase I trial and clinical pharmacological evaluation of 10-ethyl-10-deazaaminopterin in adult patients with advanced cancer. Cancer Res. 1988; 48(19):5573-9. View